Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) - Volume 23, Issue 8, 2023

After cardiovascular disease, cancer is the most common cause of death worldwide. Due to their versatility, heterocyclic compounds play an important role in drug discovery. Medical remedies are constantly being discovered, especially for catastrophic disorders such as cancer. Here, this review is focused on sulphur containing heterocyclic compounds as anticancer agents. Sulphur is found in a variety of vitamin cofactors, Read More

Objectives: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and accounts for ~90% of cases, with an approximated incidence of >1 million cases by 2025. Currently, the backbone of HCC therapy is the oral multi-kinase inhibitor, Sorafenib, which consists of a Pyridine heterocycle ring system. This review highlights the introspective characteristics of seven anticancer drugs of heterocyclic natur Read More

The current study demonstrates amygdalin’s (vitamin B17) postulated mechanism of action on cancer cells where it kills cells by selective toxicity, promotes apoptosis via cell cycle arrest, induces apoptosis via intrinsic cell death pathway (the mitochondria-initiated pathway), and enhances immunity. Thus, amygdalin can be considered a valuable natural cancer therapeutic agent. The toxicity of Amygdalin was reviewed. Mor Read More

Presently, several protein kinases have been discovered with the aim to treat various cancers. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that plays a role in the pathogenesis of a wide variety of human cancers known as ALCLs, NSCLC, ovarian cancer, breast cancer, colorectal cancer, neuroblastoma, etc. The fulllength ALK receptor is a classical receptor tyrosine kinase composed of an amino-termin Read More

Aims: Retrospective clinical studies have shown that opioids could potentially affect the risk of cancer recurrence and metastasis. Better understanding of the effects of opioids on cancer will help to select the optimal anesthetic regimens to achieve better outcomes in cancer patients. Background: Increasing evidence has shown the direct effects of opioids on bulk cancer cells and cancer stem cells. Opioid such as nalb Read More

Background: Tamoxifen is the most commonly used hormonal treatment for ERα-positive breast cancer. Tamoxifen resistance is still a big problem for ERα target therapy. RBP7 is a member of the cellular retinol-binding protein family. Objective: This study aims to investigate the prognostic role of RBP7 and the relationship between RBP7 expression and sensitivity or resistance to tamoxifen in ERα-positive breast cancer. Methods Read More

Background: Glioblastoma multiforme (GBM) is a lethal form of central nervous system cancer with a lack of efficient therapy options. Aggressiveness and invasiveness of the GBM result in poor prognosis and low overall survival. Therefore, the necessity to develop new anti-carcinogenic agents in GBM treatment is still a priority for researchers. Ion channels are one of the primary regulators of physiological h Read More

Background: Heterozygous mutations in the cytoplasmic and mitochondrial isoforms of isocitrate dehydrogenase enzymes 1 and 2 subtypes have been extensively exploited as viable druggable targets, as they decrease the affinity of isocitrate and higher affinity of D-2-hydroxyglutarate, an oncometabolite. Objective: Vorasidenib (AG-881) has recently been reported as a promising dual inhibitor of mutant isocitrate dehydrog Read More

Background: The success of drug treatment of colon cancer (CC), which is in the top three in terms of incidence and mortality among all cancers, is adversely affected by reasons, such as severe side effects and chemoresistance. Clinical, epidemiological and experimental studies have indicated the need for developing new alternative drugs for the treatment of CC. Plants are an important source of traditional medicines that hav Read More

This application describes the synthesis of new 1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione derivatives and methods of using these compounds as KRAS covalent inhibitors. This class of compounds is useful for treating cancer and other diseases associated with KRAS activity.